{
  "pmcid": "9985721",
  "sha256": "fa80a625e2fdc4065c87d6cc576666e01faf76647135ce3aeabdf22202a01a22",
  "timestamp_utc": "2025-11-09T23:03:09.021451+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.201401098901101,
    "reading_ease": 19.707884615384614,
    "word_count": 208
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Acceptable Uncertainty in Skipping Intravenous Thrombolysis Before Endovascular Treatment"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "comparing IVT+EVT (standard care) with EVT alone (experimental arm)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the acceptable level of uncertainty for skipping intravenous thrombolysis (IVT) before endovascular treatment (EVT) in stroke patients directly admitted to EVT-capable centers."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "where both arms achieved similar functional independence at 90 days"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Out of 600 invited participants, 180 responded (response rate: 30%)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "with 165 providing complete answers"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The median acceptable uncertainty for reasonable comparability was an absolute difference of 3% in the rate of day 90 functional independence (mode 5%, IQR 1â€“5%). Interventionalists chose higher margins (aOR 2.20, 95% CI 1.06 to 4.67)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not applicable."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}